O&G Forum

OBSTETRICS & GYNAECOLOGY FORUM 2021 | ISSUE 3 | 17 Medi Challenge conrms its commitment to provide safe and effective support to women throughout all phases of their lives. We are proud to announce extended approved indications and routes of administration. Indications: 1 In addition to its use for Hormone Replacement Therapy in menopause (oral) we have obtained the following indications for vaginal administration: • Threatened early miscarriage or repeated miscarriage due to luteal phase insufciency • Progesterone replacement therapy in cases of ovarian insufciency or complete ovarian failure • Supplementation of the luteal phase in cases of spontaneous or induced cycles, or primary or secondary sterility, particularly due to dysovulation • Supplementation of the luteal phase during IVF cycles Pharmacokinetic properties: 1 • UTROGESTAN® is to be inserted deep into the vagina • UTROGESTAN® is rapidly absorbed by the vaginal mucosa following vaginal insertion • UTROGESTAN® acts on the endometrium by converting the proliferating phase to the secretory • Maximum plasma concentration is reached two to six hours after administration and remains stable at physiological concentrations similar to those observed during the luteal phase of normal ovulatory menstrual cycle or those described during the rst trimester of pregnancy subject to the indication and the dosage regime MEDI CHALLENGE (PTY) LTD Fancourt Office Park, North Riding, Johannesburg. www.medichallenge.co.za For more information on UTROGESTAN® or to obtain full Product Information please contact Medical Department at denitza@medichallenge.co.za. References: 1. UTROGESTAN® PI Nappi Code Medicine Schedule Active ingredient Strength Dosage Form Quantity 851957-005 717195-001 Product UTROGESTAN UTROGESTAN S4 S4 Capsules Capsules 100 mg 200 mg Micronised progesterone Micronised progesterone 30 15 STANDING BY WOMEN FROM FERTILITY THROUGH MATERNITY INTO MENOPAUSE Reg. No: 29/21.8.2/0215; A40/21.8.2/0771 Micronised progesterone